Despite an already strong run, Hua Medicine (Shanghai) Ltd. (HKG:2552) shares have been powering on, with a gain of 39% in the last thirty days. The last month tops off a massive increase of 181% in the last year.
Following the firm bounce in price, given around half the companies in Hong Kong’s Pharmaceuticals industry have price-to-sales ratios (or “P/S”) below 2.1x, you may consider Hua Medicine (Shanghai) as a stock to avoid entirely with its 14.3x P/S ratio. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.
Check out our latest analysis for Hua Medicine (Shanghai)
What Does Hua Medicine (Shanghai)’s Recent Performance Look Like?
Recent times have been quite advantageous…
